Symbiotec Pharmalab IPO: dates, price band, lot size and GMP
Symbiotec Pharmalab IPO listed on 1 Sep at ₹988 (NSE, BSE). Issue dates 24 – 27 Aug 2026, price band ₹988, lot 15 shares. The shares now trade on the exchange; any pre-IPO price on this site is historical.
Listing: Symbiotec Pharmalab listed on 1 Sep 2026 on NSE, BSE at ₹988, ₹0 (0.0%) against the ₹988 upper band. Symbiotec Pharmalab IPO listing date, price and gain · Recently listed IPOs
Updated 17 Oct 2026, 22:10 IST. Unofficial grey-market figures, dated.
BuyUnlistedShares tracks 208 IPOs on its calendar; the Symbiotec Pharmalab IPO has a price band of ₹988, a lot of 15 shares and no grey-market premium reported yet as of 17 Oct 2026.
Key details
| Board | Mainboard |
|---|---|
| Issue dates | 24 – 27 Aug 2026 |
| Price band | ₹988 |
| Lot size | 15 shares |
| Issue size | ₹1,757.00 Cr |
| Fresh issue | ₹150 Cr |
| Offer for sale | ₹1,607 Cr |
| Subscription | 75.08x |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead managers | JM Financial Ltd., Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt.Ltd. |
| Status | Listed |
Timeline
- Issue opens: 24 Aug
- Issue closes: 27 Aug
- Allotment: 28 Aug
- Refunds: 31 Aug
- Demat credit: 31 Aug
- Listing: 1 Sep
Live subscription
| Category | Subscribed |
|---|---|
| QIB | 181.2x |
| NII | 77.56x |
| sNII | 58.01x |
| bNII | 87.34x |
| Retail | 13.69x |
| Total | 75.08x |
Last updated 27 Aug 2026, 6:55 PM IST.
Issue details
| Face value | ₹2 |
|---|---|
| Issue type | Book Build Issue |
| Listing at | NSE, BSE |
| Market cap at the upper band | ₹6,244.43 Cr |
| P/E (pre-issue) | 55.44x |
| P/E (post-issue) | 56.81x |
| Fresh issue (shares) | 15,21,261 |
| Offer for sale (shares) | 1,62,65,181 |
| Total shares offered | 1,77,86,442 |
| Promoter holding pre-issue | 36.39% |
| Promoter holding post-issue | 33.28% |
| Promoters | Anil Satwani, Kashish Satwani, Sushil Satwani, Satwani Holdings LLP |
| Lead managers | JM Financial Ltd., Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt.Ltd. |
| Registrar phone | 022-49186000 |
| Registrar email | symbiotecpharmalab.ipo@in.mpms.mufg.com |
| Company website | symbiotec.com |
| Anchor bid date | 21 Aug 2026 |
| Anchor lock-in ends (50%) | 27 Sep 2026 |
| Anchor lock-in ends (remaining) | 26 Nov 2026 |
Lot sizes by investor category
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (minimum) | 1 | 15 | ₹14,820 |
| Retail (maximum) | 14 | 210 | ₹2,07,480 |
| sNII (minimum) | 14 | 210 | ₹2,07,480 |
| bNII (minimum) | 68 | 1,020 | ₹10,07,760 |
Reservation
| Category | Share of issue | Shares offered | Basis |
|---|---|---|---|
| Anchor Investor | 29.9% | 53,25,909 | |
| QIB | 20% | 35,50,607 | Not more than 50% of the Net Offer |
| NII (HNI) | 15% | 26,62,956 | Not less than 15% of the Net Offer |
| sNII | 5% | 8,87,652 | |
| bNII | 10% | 17,75,304 | |
| Retail | 34.9% | 62,13,563 | Not less than 35.00% of the Net Offer |
| Employee | 0.2% | 33,407 |
Subscription by day
| Day | QIB | NII | sHNI | bHNI | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 · 24 Aug | 0.37x | 1.10x | 1.66x | 0.82x | 1.01x | 0.85x |
| Day 2 · 25 Aug | 0.57x | 3.16x | 4.30x | 2.59x | 2.22x | 1.95x |
| Day 3 · 26 Aug | 0.62x | 12.86x | 14.78x | 11.90x | 5.38x | 5.62x |
| Day 4 · 27 Aug | 181.20x | 77.56x | 58.01x | 87.34x | 13.69x | 75.08x |
Key ratios as of 31 Mar 2025
| EPS (pre-issue) | ₹17.82 |
|---|---|
| EPS (post-issue) | ₹17.39 |
| P/E (pre-issue) | 55.44x |
| P/E (post-issue) | 56.81x |
| RoNW | 11.79% |
| RoCE | 11.8% |
| RoE | 12.66% |
| PAT margin | 12.8% |
| EBITDA margin | 27.26% |
| Price / book | 6.58x |
| NAV per share | ₹150.17 |
| Market cap (upper band) | ₹6,244.43 Cr |
Financials (₹ Cr)
| Metric | FY26 | FY25 | FY24 | FY26 vs FY25 |
|---|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 | +12.7% |
| Total Income | 872.26 | 755.98 | 723.33 | +15.4% |
| Profit After Tax | 109.9 | 96.79 | 100.06 | +13.5% |
| EBITDA | 231.97 | 206.11 | 177.04 | +12.5% |
| NET Worth | 1,158.64 | 821.15 | 720.68 | +41.1% |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 | +41.5% |
| Total Borrowing | 387.91 | 540.92 | 247.21 | −28.3% |
About Symbiotec Pharmalab
Symbiotec Pharmalab Ltd. is an integrated pharmaceutical and biotechnology company focused on the research, development, and manufacturing of active pharmaceutical ingredients (APIs), nutraceutical ingredients, and specialty healthcare products. The company serves customers across both regulated and emerging international markets, supplying products to the pharmaceutical, nutraceutical, and wellness sectors. The company combines scientific expertise, stringent quality standards, and sustainable manufacturing practices to deliver innovative and high-quality ingredients that meet global regulatory requirements.
Through its research-oriented approach, Symbiotec continues to expand its product portfolio and strengthen its presence in international markets. With more than three decades of industry experience, Symbiotec has transformed from a laboratory-scale manufacturer of steroidal-hormone APIs in 1995 into a large-scale, backward-integrated manufacturing platform. The company has obtained approvals and certifications from major global regulatory authorities, including the US FDA, EU-GMP, the Ministry of Food and Drug Safety (South Korea), and several other international agencies.
As of June 30, 2025, Symbiotec operated two industrial-scale API manufacturing facilities with a combined chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres (KL).
Objects of the issue
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company — ₹112.5 Cr
- General Corporate Purposes — ₹29.53 Cr
- Issue Expenses — ₹105.02 Cr
Net proceeds: ₹247.05 Cr
Peer comparison
| Company | EPS (Basic) | EPS (Diluted) | NAV (₹ per share) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Symbiotec Pharmalab (issuer) | 19.1 | 19 | 184.69 | — | 9.48% | — | — |
| Concord Biotech | 24.78 | 24.78 | — | 61.07x | 14% | — | — |
| Divi's Laboratories | 96.75 | 96.75 | 631 | 87.8x | 16.5% | 13.46 | — |
| Cohance Lifesciences | 4.69 | 4.68 | — | 95.02x | 7% | — | — |
| Laurus Labs | 16.47 | 16.45 | — | 109.36x | 16.8% | — | — |
Notes: P/E Ratio has been computed based on the closing market price of equity shares on August 17, 2026, divided by the diluted EPS. Return on Net Worth is calculated as profit for the year attributable to owners of the parent company divided by the Net Worth as at the end of the respective year. Net Asset Value per share is calculated as Net Worth as at year divided by the number of Equity Shares outstanding as at the end of the year.
Offer documents: DRHP (PDF) · RHP (PDF)
Frequently asked questions
When does the Symbiotec Pharmalab IPO open and close?
The issue is scheduled for 24 – 27 Aug 2026.
What is the Symbiotec Pharmalab IPO price band?
The price band is ₹988 per share with a lot size of 15 shares.
How big is the Symbiotec Pharmalab IPO?
The total issue size is ₹1,757.00 Cr, of which ₹150 Cr is a fresh issue and ₹1,607 Cr an offer for sale.
When will Symbiotec Pharmalab list?
The tentative listing date is 1 Sep on the main board.
How do I apply for the Symbiotec Pharmalab IPO?
Apply through your broker or bank using ASBA or UPI within the issue window; the amount stays blocked in your account until allotment. BuyUnlistedShares does not take applications; it tracks the issue and the unlisted price before it.
Sources
- Draft red herring prospectus (DRHP), Symbiotec Pharmalab · as filed with SEBI · sebi.gov.in
- Red herring prospectus (RHP), Symbiotec Pharmalab · as filed · sebi.gov.in
- Registrar allotment page, MUFG Intime India Pvt.Ltd. · allotment 28 Aug · in.mpms.mufg.com
- NSE public issues page · listing 1 Sep · nseindia.com
- BSE public issues page · listing 1 Sep · bseindia.com
- Symbiotec Pharmalab company website · symbiotec.com
- BuyUnlistedShares IPO record: GMP, subscription and allotment, dated daily · GMP as of 1 Sep, 04:06 · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “Symbiotec Pharmalab IPO”, https://buyunlistedshares.com/ipo/symbiotec-pharmalab-ipo, as of 17 Oct 2026.
Other IPOs on the calendar
- Zetwerk IPO · 15 – 19 Oct 2026
- Bonfiglioli Transmissions IPO · 15 – 19 Oct 2026
- Tonbo Imaging India IPO · 15 – 19 Oct 2026
- Shellz India IPO · 15 – 19 Oct 2026
- Sahajanand Medical Technologies IPO · 15 – 19 Oct 2026
- Jio Platforms IPO · 21 – 23 Oct 2026
- Jio Platforms IPO · 21 – 23 Oct 2026
- Paras Healthcare IPO · 21 – 23 Oct 2026
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk, run by Gayatri Financial Synergy LLP. In the market since 2002. Data as of 17 Oct 2026.
Guides for IPO applicants and pre-IPO holders
- The risks of buying unlisted and pre-IPO shares in India
- Unlisted Shares Lock-In Period: What Every Investor Must Know (2026)
- What Happens to Your Unlisted Shares After the IPO? Lock-In Periods Explained
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Guides: Start investing · Evaluate a company · How prices are set · Risks · Lock-in periods · After the IPO · Sell ESOPs · NRI investors · Buybacks · Choosing a platform
BuyUnlistedShares (BUS) · Gayatri Financial Synergy LLP (LLPIN ACU-4678) · SCO-39, 1st Floor, HUDA Market, Sector-7, Faridabad, Haryana 121006 · +91 916-916-59-59
